You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普醫療(300003.SZ)2019年度淨利潤預增38%-52%
格隆匯 02-02 17:19

格隆匯2月2日丨樂普醫療(300003.SZ)公佈,預計2019年度歸屬於上市公司股東的淨利潤16.82億元-18.52億元,同比增長38%-52%。業績變動原因如下:

1、2019年,公司業務整體較上年持續增長。主營業務增長帶來的歸屬於上市公司股東的淨利潤預計較上年同期同口徑的11.66億元約有28%至43%之間的增長。

2、2019年,預計非經常性損益對公司歸屬於上市公司股東的淨利潤影響金額約4.7億元,與上年同期的1.69億元相比有明顯增加。主要是確認上海君實生物醫藥科技股份有限公司相關的已實現投資收益和未實現浮動收益及收到各類政府補助等因素所致。

3、公司按照證監會《會計監管風險提示第8 號——商譽減值》及企業會計準則的相關要求對所有投資形成的商譽及相關資產狀況進行系統性減值測試。基於現階段的審慎評估,預計計提不超過3億元。上述評估系公司初步測算結果,尚須經會計師事務所審計。

綜合上述公司主營業務產生的淨利潤、非經常性損益的貢獻及特定減值準備的計提,預計報告期內公司實現歸屬於上市公司股東的淨利潤較去年同期約有38%至52%的增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account